By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ThromboGenics NV 

Gaston Geenslaan 1

Heverlee    B-3001  Belgium
Phone: 32-0-16-751310 Fax: 32-0-16-751311


SEARCH JOBS








Company News
ThromboGenics NV (TBGNF) Achieves Important Milestone In The Development Of THR-149, A Novel Plasma Kallikrein Inhibitor For Diabetic Macular Edema 4/20/2017 10:37:29 AM
Bicycle Therapeutics Announces A Candidate Preclinical Milestone In Its Ophthalmology Alliance With ThromboGenics NV (TBGNF) 4/20/2017 6:28:46 AM
ThromboGenics NV (TBGNF) Business Update – FY 2016 3/16/2017 11:52:13 AM
ThromboGenics NV (TBGNF) Release: Pharma Enrolls First Patients In Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) For Diabetic Macular Edema (DME) 1/10/2017 9:56:50 AM
ThromboGenics NV (TBGNF) Announces Protocol Amendment To Phase II CIRCLE Trial Evaluating THR-409 (Ocriplasmin) In Patients With Non-Proliferative Diabetic Retinopathy (NPDR) 12/28/2016 9:12:06 AM
ThromboGenics NV (TBGNF) Business Update – Q3 2016 10/20/2016 11:48:46 AM
Latest ThromboGenics NV (TBGNF)' Clinical Data To Be Presented At American Academy of Ophthalmology (AAO) Meeting In Chicago 10/12/2016 9:38:16 AM
ThromboGenics NV (TBGNF) Presenting New Ophthalmic Research Data 9/7/2016 3:15:03 PM
ThromboGenics NV (TBGNF) Presenting New Ophthalmic Research Data At 16th EURETINA Congress In Copenhagen 9/7/2016 11:52:49 AM
ThromboGenics NV (TBGNF) Business Update – H1 2016 8/25/2016 10:14:40 AM
123456789
//-->